HLA-G and myeloid sarcoma: However, in light of numerous previous findings pointing out sHLA-G's role in modulating immunotolerance in MS (6, 21, 22, 24, 30, 35, 36), we suggest that sHLA-G contributes to NTZ treatment outcome in patients with RRMS and that such contribution would be particularly noticeable when considering MRI activity; therefore, we stress the need for further confirmation by larger cohort size.